{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:27:13Z","timestamp":1793953633968,"version":"4.8.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019256","name":"NIHR Great Ormond Street Hospital Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["1455446"],"award-info":[{"award-number":["1455446"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["RO1AR082469"],"award-info":[{"award-number":["RO1AR082469"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013465","name":"AFM-Telethon","doi-asserted-by":"publisher","award":["30039"],"award-info":[{"award-number":["30039"]}],"id":[{"id":"10.13039\/100013465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004923","name":"AFM-T\u00e9l\u00e9thon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003784","name":"Great Ormond Street Hospital for Children","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005041","name":"Universit\u00e9 Catholique de Louvain","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.nmd.2026.106420","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:27:58Z","timestamp":1774970878000},"page":"106420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Spatiotemporal DUX4 toxicity in FSHD: from epigenetic derepression to biomarker-driven targeted therapies"],"prefix":"10.1016","volume":"63","author":[{"given":"Virginie","family":"Mariot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4933-3469","authenticated-orcid":false,"given":"Robert J.","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Badiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Bugiardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2052-9361","authenticated-orcid":false,"given":"Julie","family":"Dumonceaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2026.106420_bib0001","article-title":"Facioscapulohumeral dystrophy: molecular basis and therapeutic opportunities","author":"Arends","year":"2024","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.nmd.2026.106420_bib0002","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ncl.2014.04.003","article-title":"Facioscapulohumeral muscular dystrophy","volume":"32","author":"Statland","year":"2014","journal-title":"Neurol Clin"},{"key":"10.1016\/j.nmd.2026.106420_bib0003","first-page":"1735","article-title":"Facioscapulohumeral muscular dystrophy","volume":"28","author":"k","year":"2022","journal-title":"Contin (Minneap Minn)"},{"key":"10.1016\/j.nmd.2026.106420_bib0004","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1212\/WNL.0000000000002217","article-title":"Milder phenotype in facioscapulohumeral dystrophy with 7-10 residual D4Z4 repeats","volume":"85","author":"Statland","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2026.106420_bib0005","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1212\/WNL.0000000000006819","article-title":"Early onset as a marker for disease severity in facioscapulohumeral muscular dystrophy","volume":"92","author":"Goselink","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2026.106420_bib0006","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1093\/brain\/awab326","article-title":"Predictors of functional outcomes in patients with facioscapulohumeral muscular dystrophy","volume":"144","author":"Katz","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2026.106420_bib0007","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12891-021-04134-7","article-title":"Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy","volume":"22","author":"Wang","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.nmd.2026.106420_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2025.105274","article-title":"Muscle imaging in facioscapulohumeral muscular dystrophy research: a scoping review and expert recommendations","volume":"47","author":"Vincenten","year":"2025","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2026.106420_bib0009","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/ng1262","article-title":"Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy","volume":"35","author":"van Overveld","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0010","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ana.20625","article-title":"Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy","volume":"58","author":"van Overveld","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2026.106420_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000559","article-title":"Specific loss of histone H3 lysine 9 trimethylation and HP1gamma\/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD)","volume":"5","author":"Zeng","year":"2009","journal-title":"PLoS Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0012","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ng999","article-title":"Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere","volume":"32","author":"Lemmers","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0013","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/jmg.2006.042804","article-title":"A large patient study confirming that facioscapulohumeral muscular dystrophy (FSHD) disease expression is almost exclusively associated with an FSHD locus located on a 4qA-defined 4qter subtelomere","volume":"44","author":"Thomas","year":"2007","journal-title":"J Med Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0014","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1189044","article-title":"A unifying genetic model for facioscapulohumeral muscular dystrophy","volume":"329","author":"Lemmers","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.nmd.2026.106420_bib0015","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ng.2454","article-title":"Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2","volume":"44","author":"Lemmers","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0016","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-1119(99)00267-X","article-title":"Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element","volume":"236","author":"Gabriels","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.nmd.2026.106420_bib0017","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1128\/MCB.00149-14","article-title":"Myogenic enhancers regulate expression of the facioscapulohumeral muscular dystrophy-associated DUX4 gene","volume":"34","author":"Himeda","year":"2014","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.nmd.2026.106420_bib0018","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1086\/519311","article-title":"Evolutionary conservation of a coding function for D4Z4, the tandem DNA repeat mutated in facioscapulohumeral muscular dystrophy","volume":"81","author":"Clapp","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0019","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/hmg\/ddy364","article-title":"MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD","volume":"28","author":"Wang","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0020","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1093\/hmg\/ddaa164","article-title":"Skeletal muscle regeneration in facioscapulohumeral muscular dystrophy is correlated with pathological severity","volume":"29","author":"Banerji","year":"2020","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001181","article-title":"Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene","volume":"6","author":"Snider","year":"2010","journal-title":"PLoS Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0022","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/hmg\/ddv315","article-title":"Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways","volume":"24","author":"Rickard","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0023","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41598-022-04817-8","article-title":"Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers","volume":"12","author":"van den Heuvel","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.nmd.2026.106420_bib0024","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13395-025-00388-0","article-title":"DUX4 at 25: how it emerged from \"junk DNA\" to become the cause of facioscapulohumeral muscular dystrophy","volume":"15","author":"Belayew","year":"2025","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.nmd.2026.106420_bib0025","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/WCO.0000000000001382","article-title":"Recent progress in the molecular understanding and treatments of facioscapulohumeral muscular dystrophy","volume":"38","author":"Augustinus","year":"2025","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.nmd.2026.106420_bib0026","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41582-022-00762-2","article-title":"Facioscapulohumeral muscular dystrophy: the road to targeted therapies","volume":"19","author":"Tihaya","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.nmd.2026.106420_bib0027","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/ng.3858","article-title":"DUX-family transcription factors regulate zygotic genome activation in placental mammals","volume":"49","author":"De Iaco","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0028","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/hmg\/ddt409","article-title":"DUX4 and DUX4 downstream target genes are expressed in fetal FSHD muscles","volume":"23","author":"Ferreboeuf","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0029","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1093\/hmg\/ddt272","article-title":"Dysregulation of 4q35- and muscle-specific genes in fetuses with a short D4Z4 array linked to Facio-Scapulo-Humeral dystrophy","volume":"22","author":"Broucqsault","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1582-4934.2012.01647.x","article-title":"DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?","volume":"17","author":"Tassin","year":"2012","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.nmd.2026.106420_bib0031","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.04996","article-title":"A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy","volume":"4","author":"Feng","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.nmd.2026.106420_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112642","article-title":"Compromised nonsense-mediated RNA decay results in truncated RNA-binding protein production upon DUX4 expression","volume":"42","author":"Campbell","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.nmd.2026.106420_bib0033","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.41740","article-title":"Quantitative proteomics reveals key roles for post-transcriptional gene regulation in the molecular pathology of facioscapulohumeral muscular dystrophy","volume":"8","author":"Jagannathan","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.nmd.2026.106420_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102251","article-title":"Interplay between mitochondrial reactive oxygen species, oxidative stress and hypoxic adaptation in facioscapulohumeral muscular dystrophy: metabolic stress as potential therapeutic target","volume":"51","author":"Heher","year":"2022","journal-title":"Redox Biol"},{"key":"10.1016\/j.nmd.2026.106420_bib0035","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.freeradbiomed.2016.08.007","article-title":"DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients","volume":"99","author":"Dmitriev","year":"2016","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.nmd.2026.106420_bib0036","doi-asserted-by":"crossref","DOI":"10.1242\/bio.059145","article-title":"Downstream events initiated by expression of FSHD-associated DUX4: studies of nucleocytoplasmic transport, gammaH2AX accumulation, and Bax\/Bak-dependence","volume":"11","author":"Masteika","year":"2022","journal-title":"Biol Open"},{"key":"10.1016\/j.nmd.2026.106420_bib0037","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/cge.13726","article-title":"Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy","volume":"97","author":"Greco","year":"2020","journal-title":"Clin Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0038","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13023-021-01760-1","article-title":"Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update","volume":"16","author":"Schatzl","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2026.106420_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035532","article-title":"Asymmetric bidirectional transcription from the FSHD-causing D4Z4 array modulates DUX4 production","volume":"7","author":"Block","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2026.106420_bib0040","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1093\/nar\/gkaa146","article-title":"G-quadruplex ligands mediate downregulation of DUX4 expression","volume":"48","author":"Ciszewski","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.nmd.2026.106420_bib0041","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13395-024-00361-3","article-title":"SIX transcription factors are necessary for the activation of DUX4 expression in facioscapulohumeral muscular dystrophy","volume":"14","author":"Fox","year":"2024","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.nmd.2026.106420_bib0042","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1093\/nar\/gkad230","article-title":"WDR5 is required for DUX4 expression and its pathological effects in FSHD muscular dystrophy","volume":"51","author":"Mocciaro","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.nmd.2026.106420_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2022.166367","article-title":"The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy","volume":"1868","author":"Jagannathan","year":"2022","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.nmd.2026.106420_bib0044","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/hmg\/ddh205","article-title":"Localization of 4q35.2 to the nuclear periphery: is FSHD a nuclear envelope disease?","volume":"13","author":"Masny","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000394","article-title":"The D4Z4 macrosatellite repeat acts as a CTCF and A-type lamins-dependent insulator in facio-scapulo-humeral dystrophy","volume":"5","author":"Ottaviani","year":"2009","journal-title":"PLoS Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0046","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nsmb.2571","article-title":"Telomere position effect regulates DUX4 in human facioscapulohumeral muscular dystrophy","volume":"20","author":"Stadler","year":"2013","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.nmd.2026.106420_bib0047","first-page":"94","article-title":"Epigenetic mechanisms of facioscapulohumeral muscular dystrophy","volume":"647","author":"de Greef","year":"2008","journal-title":"Mutat Res"},{"key":"10.1016\/j.nmd.2026.106420_bib0048","doi-asserted-by":"crossref","DOI":"10.1101\/gr.190660.115","article-title":"SORBS2 transcription is activated by telomere position effect-over long distance upon telomere shortening in muscle cells from patients with facioscapulohumeral dystrophy","author":"Robin","year":"2015","journal-title":"Genome Res"},{"key":"10.1016\/j.nmd.2026.106420_bib0049","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1093\/hmg\/ddu129","article-title":"Nuclear protein spreading: implication for pathophysiology of neuromuscular diseases","volume":"23","author":"Ferreboeuf","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0050","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.88345","article-title":"An in silico FSHD muscle fiber for modeling DUX4 dynamics and predicting the impact of therapy","volume":"12","author":"Cowley","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.nmd.2026.106420_bib0051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008754","article-title":"Single-nucleus RNA-seq identifies divergent populations of FSHD2 myotube nuclei","volume":"16","author":"Jiang","year":"2020","journal-title":"PLoS Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0052","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.celrep.2019.10.025","article-title":"DUX4-Induced histone variants H3.X and H3.Y mark DUX4 target genes for expression","volume":"29","author":"Resnick","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.nmd.2026.106420_bib0053","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/hmg\/ddad186","article-title":"snRNA-seq analysis in multinucleated myogenic FSHD cells identifies heterogeneous FSHD transcriptome signatures associated with embryonic-like program activation and oxidative stress-induced apoptosis","volume":"33","author":"Zheng","year":"2024","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0054","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1101\/gr.278717.123","article-title":"Single-cell spatial transcriptomics reveals a dystrophic trajectory following a developmental bifurcation of myoblast cell fates in facioscapulohumeral muscular dystrophy","volume":"34","author":"Chen","year":"2024","journal-title":"Genome Res"},{"key":"10.1016\/j.nmd.2026.106420_bib0055","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/mus.24621","article-title":"Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies","volume":"52","author":"Statland","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2026.106420_bib0056","doi-asserted-by":"crossref","DOI":"10.1063\/5.0189221","article-title":"Engineering interfacial tissues: the myotendinous junction","volume":"8","author":"Snow","year":"2024","journal-title":"APL Bioeng"},{"key":"10.1016\/j.nmd.2026.106420_bib0057","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s42003-024-06325-z","article-title":"Meta-analysis towards FSHD reveals misregulation of neuromuscular junction, nuclear envelope, and spliceosome","volume":"7","author":"Schatzl","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.nmd.2026.106420_bib0058","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1093\/hmg\/ddu251","article-title":"DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle","volume":"23","author":"Yao","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0059","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jama.2016.2240","article-title":"Biomarkers and surrogate endpoints: developing common terminology and definitions","volume":"315","author":"Robb","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2026.106420_bib0060","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.nmd.2026.106420_bib0061","first-page":"22","article-title":"265th ENMC international workshop: muscle imaging in Facioscapulohumeral Muscular dystrophy (FSHD): relevance for clinical trials","author":"Monforte","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2026.106420_bib0062","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nmd.2023.04.005","article-title":"268th ENMC workshop - genetic diagnosis, clinical classification, outcome measures, and biomarkers in Facioscapulohumeral Muscular Dystrophy (FSHD): relevance for clinical trials","volume":"33","author":"Montagnese","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2026.106420_bib0063","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1093\/hmg\/dds284","article-title":"Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis","volume":"21","author":"Jones","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0064","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/mt.2016.111","article-title":"Morpholino-mediated knockdown of DUX4 toward facioscapulohumeral muscular dystrophy therapeutics","volume":"24","author":"Chen","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.nmd.2026.106420_bib0065","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13104-022-06054-8","article-title":"Proximity ligation assay to detect DUX4 protein in FSHD1 muscle: a pilot study","volume":"15","author":"Beermann","year":"2022","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.nmd.2026.106420_bib0066","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/hmg\/ddae007","article-title":"Regional and bilateral MRI and gene signatures in facioscapulohumeral dystrophy: implications for clinical trial design and mechanisms of disease progression","volume":"33","author":"Wong","year":"2024","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0067","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1038\/emboj.2008.201","article-title":"An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies","volume":"27","author":"Bosnakovski","year":"2008","journal-title":"Embo J"},{"key":"10.1016\/j.nmd.2026.106420_bib0068","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/s41467-017-01200-4","article-title":"PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle","volume":"8","author":"Banerji","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.nmd.2026.106420_bib0069","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad221","article-title":"The FSHD muscle-blood biomarker: a circulating transcriptomic biomarker for clinical severity in facioscapulohumeral muscular dystrophy","volume":"5","author":"Banerji","year":"2023","journal-title":"Brain Commun"},{"key":"10.1016\/j.nmd.2026.106420_bib0070","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/hmg\/ddz043","article-title":"PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level","volume":"28","author":"Banerji","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113011","article-title":"Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy","volume":"320","author":"Mueller","year":"2019","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nmd.2026.106420_bib0072","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13395-016-0078-6","article-title":"Neuromuscular electrical stimulation promotes development in mice of mature human muscle from immortalized human myoblasts","volume":"6","author":"Sakellariou","year":"2016","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.nmd.2026.106420_bib0073","article-title":"Biological biomarkers in muscle diseases relevant for follow-up and evaluation of treatment","author":"Stemmerik","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2026.106420_bib0074","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad235","article-title":"Facioscapulohumeral muscular dystrophy's game of homeodomains: therapy wants a biomarker as a sword wants a whetstone","volume":"5","author":"Kyba","year":"2023","journal-title":"Brain Commun"},{"key":"10.1016\/j.nmd.2026.106420_bib0075","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41526-018-0057-9","article-title":"IL-6 and the dysregulation of immune, bone, muscle, and metabolic homeostasis during spaceflight","volume":"4","author":"Smith","year":"2018","journal-title":"NPJ Microgravity"},{"key":"10.1016\/j.nmd.2026.106420_bib0076","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1210\/endrev\/bnaa016","article-title":"Muscle-organ crosstalk: the emerging roles of myokines","volume":"41","author":"Severinsen","year":"2020","journal-title":"Endocr Rev"},{"key":"10.1016\/j.nmd.2026.106420_bib0077","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1186\/s40064-016-2197-2","article-title":"Skeletal muscle wasting and renewal: a pivotal role of myokine IL-6","volume":"5","author":"Belizario","year":"2016","journal-title":"Springerplus"},{"key":"10.1016\/j.nmd.2026.106420_bib0078","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.nmd.2026.106420_bib0079","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3233\/JND-210711","article-title":"Identification of serum interleukin 6 levels as a disease severity biomarker in facioscapulohumeral muscular dystrophy","volume":"9","author":"Gros","year":"2022","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2026.106420_bib0080","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/JND-230063","article-title":"IL-6 and TNF are potential inflammatory biomarkers in facioscapulohumeral muscular dystrophy","volume":"11","author":"Greco","year":"2024","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2026.106420_bib0081","article-title":"Interleukin-6 as a key biomarker in facioscapulohumeral dystrophy: evidence from longitudinal analyses","author":"Pini","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2026.106420_bib0082","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/sms.14241","article-title":"IL-6 signaling in acute exercise and chronic training: potential consequences for health and athletic performance","volume":"33","author":"Nash","year":"2023","journal-title":"Scand J Med Sci Sports"},{"key":"10.1016\/j.nmd.2026.106420_bib0083","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165799","article-title":"Diurnal variation of circulating interleukin-6 in humans: a meta-analysis","volume":"11","author":"Nilsonne","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2026.106420_bib0084","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1113\/jphysiol.1997.sp021972","article-title":"Exercise-induced increase in serum interleukin-6 in humans is related to muscle damage","volume":"499","author":"Bruunsgaard","year":"1997","journal-title":"J Physiol"},{"key":"10.1016\/j.nmd.2026.106420_bib0085","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/387083a0","article-title":"Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member","volume":"387","author":"McPherron","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.nmd.2026.106420_bib0086","doi-asserted-by":"crossref","first-page":"12457","DOI":"10.1073\/pnas.94.23.12457","article-title":"Double muscling in cattle due to mutations in the myostatin gene","volume":"94","author":"McPherron","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nmd.2026.106420_bib0087","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41467-017-01486-4","article-title":"Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches","volume":"8","author":"Mariot","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.nmd.2026.106420_bib0088","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00415-016-8379-6","article-title":"Reduced serum myostatin concentrations associated with genetic muscle disease progression","volume":"264","author":"Burch","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2026.106420_bib0089","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.nmd.2023.01.001","article-title":"Myostatin and follistatin as monitoring and prognostic biomarkers in dysferlinopathy","volume":"33","author":"Moore","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2026.106420_bib0090","doi-asserted-by":"crossref","first-page":"e975","DOI":"10.1212\/WNL.0000000000201609","article-title":"Longitudinal assessment of Creatine kinase, Creatine\/creatinine(ratio), and myostatin as monitoring biomarkers in Becker Muscular dystrophy","volume":"100","author":"van de Velde","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2026.106420_bib0091","doi-asserted-by":"crossref","DOI":"10.1111\/nan.12849","article-title":"Myostatin in idiopathic inflammatory myopathies: serum assessment and disease activity","volume":"49","author":"Mahoudeau","year":"2023","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.nmd.2026.106420_bib0092","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae062","article-title":"Serum myostatin as a candidate disease severity and progression biomarker of spinal muscular atrophy","volume":"6","author":"de Albuquerque","year":"2024","journal-title":"Brain Commun"},{"key":"10.1016\/j.nmd.2026.106420_bib0093","first-page":"25","article-title":"Impact of disease severity and disease-modifying therapies on myostatin levels in SMA patients","author":"Mackels","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nmd.2026.106420_bib0094","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.ajpath.2022.07.016","article-title":"Dystrophin restoration after adeno-associated virus U7-mediated dmd exon skipping is modulated by muscular exercise in the severe D2-mdx Duchenne muscular dystrophy murine model","volume":"192","author":"Monceau","year":"2022","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2026.106420_bib0095","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.omtm.2020.06.016","article-title":"Myostatin is a quantifiable biomarker for monitoring pharmaco-gene therapy in Duchenne muscular dystrophy","volume":"18","author":"Mariot","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.nmd.2026.106420_bib0096","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.omtm.2020.04.022","article-title":"Myostatin: a circulating biomarker correlating with disease in myotubular myopathy mice and patients","volume":"17","author":"Koch","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.nmd.2026.106420_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2025.106262","article-title":"Meeting report: the FSHD society 2025 international research congress","volume":"58","author":"Ronco","year":"2026","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2026.106420_bib0098","article-title":"Identification of KHDC1L, a DUX4-regulated protein, as a novel plasma biomarker in facioscapulohumeral muscular dystrophy","author":"Sutliff","year":"2025","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0099","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.tcb.2016.11.007","article-title":"Pathways of unconventional protein secretion","volume":"27","author":"Rabouille","year":"2017","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.nmd.2026.106420_bib0100","unstructured":"Biosciences\" A, delivering for people living with facioscapulohumeral muscular dystrophy (FSHD). 2025."},{"key":"10.1016\/j.nmd.2026.106420_bib0101","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13250","article-title":"Five-year follow-up study on quantitative muscle magnetic resonance imaging in facioscapulohumeral muscular dystrophy: the link to clinical outcome","author":"Vincenten","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.nmd.2026.106420_bib0102","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/hmg\/ddaa031","article-title":"Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies","volume":"29","author":"Wong","year":"2020","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2026.106420_bib0103","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s00415-025-13062-8","article-title":"Natural history of facioscapulohumeral muscular dystrophy evaluated by multiparametric quantitative MRI: a prospective cohort study","volume":"272","author":"Paoletti","year":"2025","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2026.106420_bib0104","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1111\/ene.14863","article-title":"The facioscapulohumeral muscular dystrophy Rasch-built overall disability scale (FSHD-RODS)","volume":"28","author":"Mul","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2026.106420_bib0105","doi-asserted-by":"crossref","DOI":"10.1002\/mus.26088","article-title":"Facioscapulohumeral muscular dystrophy functional composite outcome measure","author":"Eichinger","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2026.106420_bib0106","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.nmd.2019.05.006","article-title":"Longitudinal study of upper extremity reachable workspace in fascioscapulohumeral muscular dystrophy","volume":"29","author":"Hatch","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2026.106420_bib0107","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/mus.28031","article-title":"A longitudinal study of disease progression in facioscapulohumeral muscular dystrophy (FSHD)","volume":"69","author":"Varma","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2026.106420_bib0108","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2025.105422","article-title":"The recent clinical trial of losmapimod for the treatment of facioscapulohumeral muscular dystrophy","volume":"52","author":"Bloch","year":"2025","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2026.106420_bib0109","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.119.259663","article-title":"Clinically advanced p38 inhibitors suppress DUX4 expression in cellular and animal models of facioscapulohumeral muscular dystrophy","volume":"370","author":"Oliva","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nmd.2026.106420_bib0110","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S1474-4422(24)00073-5","article-title":"Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial","volume":"23","author":"Tawil","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2026.106420_bib0111","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.046904","article-title":"Cellular and animal models for facioscapulohumeral muscular dystrophy","volume":"13","author":"DeSimone","year":"2020","journal-title":"Dis Model Mech"},{"issue":"9","key":"10.1016\/j.nmd.2026.106420_bib0112","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.3390\/jcm9092886","article-title":"Therapeutic strategies targeting DUX4 in FSHD","volume":"9","author":"Le Gall","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.nmd.2026.106420_bib0113","series-title":"Neuromuscular Study Group Annual Scientific Meeting","article-title":"Interim results from FORTITUDE, a randomized phase 1\/2 trial evaluating AOC 1020 in adults with FSHD","author":"Statland","year":"2024"},{"key":"10.1016\/j.nmd.2026.106420_bib0114","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/s41598-021-81669-8","article-title":"Novel myostatin-specific antibody enhances muscle strength in muscle disease models","volume":"11","author":"Muramatsu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.nmd.2026.106420_bib0115","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.21338","article-title":"A phase I\/IItrial of MYO-029 in adult subjects with muscular dystrophy","volume":"63","author":"Wagner","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2026.106420_bib0116","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/mus.27558","article-title":"Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy","volume":"66","author":"Statland","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2026.106420_bib0117","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1212\/WNL.50.5.1402","article-title":"Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group","volume":"50","author":"Kissel","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2026.106420_bib0118","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.57.8.1434","article-title":"Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy","volume":"57","author":"Kissel","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2026.106420_bib0119","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.apmr.2008.12.027","article-title":"Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial","volume":"90","author":"Payan","year":"2009","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.nmd.2026.106420_bib0120","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002276.pub2","article-title":"Drug treatment for facioscapulohumeral muscular dystrophy","author":"Rose","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nmd.2026.106420_bib0121","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13395-017-0134-x","article-title":"BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells","volume":"7","author":"Campbell","year":"2017","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.nmd.2026.106420_bib0122","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41591-026-04258-0","article-title":"Neurodegenerative diseases need more mechanism-informed trials","volume":"32","author":"Nm","year":"2026","journal-title":"Nat Med"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096089662600088X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096089662600088X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:01:55Z","timestamp":1793952115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096089662600088X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":122,"alternative-id":["S096089662600088X"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2026.106420","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spatiotemporal DUX4 toxicity in FSHD: from epigenetic derepression to biomarker-driven targeted therapies","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2026.106420","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106420"}}